F2G gets rejected by the FDA, which wants more data before it will approve antifungal drug, company says
The antifungal-focused biotech F2G has more work to do before it will be able to get its drug for invasive fungal infections approved by US …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
